Success Metrics

Clinical Success Rate
50.0%

Based on 1 completed trials

Completion Rate
50%(1/2)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
1(50%)

Phase Distribution

Ph phase_2
1
50%
Ph phase_4
1
50%

Phase Distribution

0

Early Stage

1

Mid Stage

1

Late Stage

Phase Distribution2 total trials
Phase 2Efficacy & side effects
1(50.0%)
Phase 4Post-market surveillance
1(50.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

50.0%

1 of 2 finished

Non-Completion Rate

50.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

2

all time

Status Distribution
Completed(1)
Terminated(1)

Detailed Status

Terminated1
Completed1

Development Timeline

Analytics

Development Status

Total Trials
2
Active
0
Success Rate
50.0%
Most Advanced
Phase 4

Trials by Phase

Phase 21 (50.0%)
Phase 41 (50.0%)

Trials by Status

terminated150%
completed150%

Recent Activity

0 active trials
Showing 2 of 2
completedphase_2

[68 Ga]-DOTANOC PET/CT in GEP-NETs

NCT02608203
terminatedphase_4

68Ga-DOTA-NOC PET/CT in Patients With Idiopathic Pulmonary Fibrosis

NCT01321996

Clinical Trials (2)

Showing 2 of 2 trials
NCT02608203Phase 2

[68 Ga]-DOTANOC PET/CT in GEP-NETs

Completed
NCT01321996Phase 4

68Ga-DOTA-NOC PET/CT in Patients With Idiopathic Pulmonary Fibrosis

Terminated

All 2 trials loaded

Drug Details

Intervention Type
PROCEDURE
Total Trials
2